Specific removal of β1-adrenoceptor autoantibodies by immunoabsorption in rabbits with autoimmune cardiomyopathy improved cardiac structure and function

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 1, 2006, Pages 78-85

  Matsui, Shinobu ^a   Larsson, Lisa ^b   Hayase, Mituru ^a   Katsuda, Shogo ^a   Teraoka, Kohei ^a   Kurihara, Takayuki ^a   Murano, Hidekazu ^a   Nishikawa, Katsuzou ^a   Fu, Michael ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

1 adrenoceptor; Autoantibody; Autoimmune cardiomyopathy; Dilated cardiomyopathy; Immunoabsorption

Indexed keywords

AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CARDIOMYOPATHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION TIME; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SIZE; IMMUNIZATION; IMMUNOADSORPTION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; ELECTROCARDIOGRAPHY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART; HEART MUSCLE; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; ORGAN SIZE; PHYSIOLOGY; ULTRASTRUCTURE;

ORYCTOLAGUS CUNICULUS;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BODY WEIGHT; CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART; IMMUNOSORBENT TECHNIQUES; IMMUNOTHERAPY; MALE; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; MYOCARDIUM; ORGAN SIZE; RABBITS; RECEPTORS, ADRENERGIC, BETA-1;

EID: 33745649192     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.04.016     Document Type: Article

References (34)

1. Zannad F., Briancon S., Juilliere Y., Mertes P.M., Villemot J.P., Alla F., et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. J. Am. Coll. Cardiol. 33 (1999) 734-742
2. Magnusson Y., Marullo S., Hoyer S., Waagstein F., Andersson B., Vahlne A., et al. Mapping of a functional autoimmune epitope on the β1-adrenergic receptor in patients with idiopathic cardiomyopathy. J. Clin. Invest. 86 (1990) 1658-1663
3. Magnusson Y., Wallukat G., Waagstein F., Hjalmarson Å., and Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 89 (1994) 2760-2767
4. Limas C.J., Goldenberg I.F., and Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. correlation with disease severity and cardiac autoantibodies. Circulation 91 (1995) 631-634
5. Caforio A.L., Gold J.H., Baig M.K., Keeling P.J., Bottazzo G.F., and McKenna W.J. Organ-specific cardiac autoantibodies in dilated cardiomyopathy-An update. Eur. Heart J. 16 Suppl. O (1995) 68-70
6. Wallukat G., Wollenberger A., Morwinski R., and Pitscher H.F. Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J. Mol. Cell. Cardiol. 27 (1995) 397-406
7. Jahns R., Boivin V., Siegmund C., Inselmann G., Lohse M.J., and Boege F. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99 (1999) 649-654
8. Fu L.X.M., Magnusson Y., Bergh C.-H., Liljeqvist J.Å., Waagstein F., Hjalmarson Å., et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest. 91 (1993) 1964-1968
9. Matsui S., Fu M.L.X., Katsuda S., Hayase M., Yamaguchi N., Teraoka K., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J. Mol. Cell. Cardiol. 29 (1997) 641-655
10. Iwata M., Yoshikawa T., Baba A., Anzai T., Nakamura I., Wainai Y., et al. Autoimmunity against the second extracellular loop of β1-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ. Res. 88 (2001) 578-586
11. Fu L.X.M., Schulze W., Wallukat G., Hjalmarson Å., and Hoebeke J. Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. J. Mol. Cell. Cardiol 27 (1995) 427-436
12. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001) 319-322
13. Jahns R., Boivin V., Hein L., Triebel S., Angermann C.E., Ertl G., et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest. 113 (2004) 1419-1429
14. Podlowski S., Luther H.P., Morwinski R., Müller J., and Wallukat G. Agonistic anti-β1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the β1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 98 (1998) 2470-2476
15. Fu L.X.M., Schulze W., Wallukat G., Hjalmarson Å., and Hoebeke J. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin. Immunol. Immunopathol. 78 (1996) 203-207
16. The CONSERNSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 316 (1987) 1429-1435
17. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325 (1991) 293-302
18. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
19. Packer M., Coats A.J., Fowler M.B., Katus H.A., Kraum H., Mohacsi P., et al. Effect of carvesilol on survival in severe chronic heart failure. N. Engl. J. Med. 344 (2001) 1651-1658
20. Wallukat G., Reinke P., Dröffel W.V., Luther H.P., Bestvater K., Felix S.B., et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int. J. Cardiol. 54 (1996) 191-195
21. Dörffel W.V., Felix S.B., Wallukat G., Brehme S., Bestvater K., Hofmann T., et al. Short-term hemodynamic effects of immunoabsorption in dilated cardiomyopathy. Circulation 95 (1997) 1994-1997
22. Müller J., Wallukat G., Dandel M., Bieda H., Brandes K., Spiegelsberger S., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000) 385-391
23. Felix S.B., Staudt A., Dörffel W.V., Stangel V., Merkel K., Pohl M., et al. Hemodynamic effects of immunoabsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J. Am. Coll. Cardiol. 35 (2000) 1590-1598
24. Staudt A., Schäper F., Stangl V., Plagemann A., Böhm M., Merkel K., et al. Immunohistological changes in dilated cardiomyopathy induced by immunoabsorption therapy and subsequent immunoglobulin substitution. Circulation 103 (2001) 2681-2686
25. Schimke I., Müller J., Priem F., Kruse I., Schön B., Stein J., et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin absorption. J. Am. Coll. Cardiol. 38 (2001) 178-183
26. Felix S.B., Staudt A., Landsberger M., Grosse Y., Stangl V., Spielhagen T., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J. Am. Coll. Cardiol. 39 (2002) 646-652
27. Staudt A., Böhm M., Knebel F., Grosse Y., Bischoff C., Hummel A., et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106 (2002) 2448-2453
28. Wallukat G., Müller J., and Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N. Engl. J. Med. 347 (2002) 1806
29. Knebel F., Bohm M., Staudt A., Borges A.C., Tepper M., Jockmann N., et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int. J. Cardiol. 97 (2004) 517-520
30. Sahn D.J., DeMaria A., Kisslo J., and Weyman A.E. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
31. Bristow M.R., Port J.D., and Gilgert E.M. The role of adrenergic receptor regulation in the treatment of heart failure. Cardiovasc. Drugs Ther. 3 (1989) 971-978
32. Tagawa Y., Yuki N., and Hirata K. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double filtration plasmapheresis and immunoabsorption. J. Neurol. Sci. 157 (1998) 90-95
33. Schneidewide J.M., Zettle U.K., Winkeler R.E., Ramlow W., Tiess M., Michelsen A., et al. The outcome in myasthenia gravis patients: an eight-year follow-up after finishing immunoabsorption therapy. Transfus. Apher. Sci. 24 (2001) 95-98
34. Shibuya N., Sato T., Osamu M., Takegami T., Doi S., and Kawanami S. Immunoabsorption therapy for myasthenia gravis. J. Neurol. Neurosurg. Pshychiary 57 (1994) 578-581